![Travaux chimiques](https://static.wixstatic.com/media/11062b_80968a2fd19c4db1b386040899f46f90~mv2.jpeg/v1/fill/w_147,h_98,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/11062b_80968a2fd19c4db1b386040899f46f90~mv2.jpeg)
![](https://static.wixstatic.com/media/11062b_d0808b670f96485a99f29e2304359ccef000.jpg/v1/fill/w_147,h_83,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/11062b_d0808b670f96485a99f29e2304359ccef000.jpg)
PALTECH: THE FIRST MEDICAL DEVICE ENABLING A SUSTAINED REMISSION OF TYPE 2 DIABETES
A NEW PARADIGM IN THE TREATMENT OF TYPE 2 DIABETES
OUR VISION : FOR A SUSTAINED LONG TERM T2D REMISSION
PALTECH DEVELOPS A NEW INNOVATIVE TREATMENT FOR TYPE 2 DIABETES
A Laparoscopically implantable medical device for people suffering from Type 2 Diabetes
Upregulation of deficient portal GLP-1 receptors
First class pre-clinical results
Filing for FIH in 2025
![](https://static.wixstatic.com/media/11062b_8bea9f5462544548af3c9818a9284c94f000.png/v1/fill/w_108,h_108,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/11062b_8bea9f5462544548af3c9818a9284c94f000.png)
PALTECH IN A NUTSHELL
Funded by an INRAE professor, Business minded Diabetologist and Entrepreneurs, with previous successful experiences
![PALTECH](https://static.wixstatic.com/media/8e8178_d60c1d9f1f814c17a0180bf66f0b33e2~mv2.png/v1/fill/w_119,h_93,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/8e8178_d60c1d9f1f814c17a0180bf66f0b33e2~mv2.png)
CREATED IN 2021
Development of the Proof Of Concept
Launch of the preclinical phase
Results already obtained in animals
Funding : Private (fund raising) and Public (2 grants from French State / BPI)
![CREATION](https://static.wixstatic.com/media/1f6dea9d4c86474bab233c51988244b0.png/v1/fill/w_93,h_112,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/1f6dea9d4c86474bab233c51988244b0.png)
![MEDTECH](https://static.wixstatic.com/media/8e8178_cccfc18de7e64ecba28efda713c5d19e~mv2.jpg/v1/fill/w_73,h_91,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/Abstract%20Wavy%20Structure_edited.jpg)
STRONG IP
3 Patents filed
SOLID SCIENTIFIC DATA PROVEN RESULTS
A solid corpus of peer reviewed data, showing a unique MOA to induce a sustained T2D remission for multiple years
![INNOVATION](https://static.wixstatic.com/media/8e8178_35f68d608bf04759aa16c836e37d1976~mv2.png/v1/fill/w_83,h_78,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/3D%20Swirl_edited.png)
![](https://static.wixstatic.com/media/8e8178_2f81647b4691488a9974a5e1c52639c6~mv2.jpg/v1/fill/w_227,h_142,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/8e8178_2f81647b4691488a9974a5e1c52639c6~mv2.jpg)
A BREAKTHROUGH FROM CURRENT PRACTICE
A Current T2D medical treatments show limited sustained efficacy due to poor adherence & persistence rates, significant adverse effects.
Metabolic surgeries are very invasive, their follow-up is resource demanding for both patients and HCPs, they are limited in numbers and provide 5 years T2D remissions in only 30-50% cases
![diabetes_edited.jpg](https://static.wixstatic.com/media/8e8178_b3d54a85a03b473491e183df1ed46f1f~mv2.jpg/v1/fill/w_123,h_69,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/8e8178_b3d54a85a03b473491e183df1ed46f1f~mv2.jpg)
DIABETES: A WORLDWIDE CONCERN
500m+
Diabetes cases
80%
1 BN
Prediabetes patients
1st
Renal Failure
Cause of Blindness
2,5x
Cardiovascular diseases death
+15%
Liver Disease Mash
T2D Direct Costs Woldwide